--- name: interpreting-ambulatory-monitoring language: en description: Structures Holter and event monitor interpretation with arrhythmia burden quantification. Use when reading Holter monitors, interpreting event recorders, or quantifying arrhythmia burden. tags: - analysis - cardiology metadata: author: casemark practice_areas: - Cardiology - Interventional Cardiology - Electrophysiology document_types: - Interpretation Report skill_modes: - Analysis - Interpretation --- # Interpreting Ambulatory Monitoring Structures Holter and event monitor interpretation with arrhythmia burden quantification. ## Why This Skill Exists Ambulatory cardiac monitoring — Holter monitors, event recorders, mobile cardiac telemetry (MCT), and implantable loop recorders (ILRs) — is the primary diagnostic tool for arrhythmia detection in patients with palpitations, syncope, cryptogenic stroke, and AF burden assessment. The choice of monitoring device depends on symptom frequency, and mismatching device to clinical question wastes diagnostic opportunity. The HRS Expert Consensus on Ambulatory ECG Monitoring provides guidelines for device selection, interpretation standards, and clinically significant findings. Structured interpretation must quantify arrhythmia burden (not just identify isolated events), correlate symptoms with rhythm, assess rate control adequacy, and identify high-risk findings requiring urgent action. Generic summaries like "occasional PVCs noted" fail the clinical standard. --- ## Checkpoint A: Pre-Draft Intake (Mandatory) 1. What is the clinical indication — palpitations, syncope, presyncope, cryptogenic stroke, AF burden assessment, rate control evaluation? (default: "Indication not specified") 2. What type of monitor was used — 24-hour Holter, 48-hour Holter, 7-day patch, event recorder, MCT, or ILR? (default: "Monitor type not specified") 3. What is the total recording duration and analyzable time? (default: "Duration not documented") 4. Did the patient keep a symptom diary? (default: "No diary available") 5. Is the patient on rate- or rhythm-control medications? (default: "Medication list not provided") 6. Is there a known arrhythmia being monitored or is this a diagnostic study? (default: "Diagnostic — no known arrhythmia") 7. Is there known structural heart disease or reduced LVEF? (default: "Structural heart disease status unknown") 8. Is there a prior monitoring study for comparison? (default: "No prior study available") ### Documents to Request - Complete ambulatory monitoring report with all pages - Representative rhythm strips (normal sinus, abnormal events, symptom-correlated events) - Patient symptom diary with timestamps - Full disclosure data access (if available for independent review) - Prior ambulatory monitoring reports for comparison - Current medication list - Recent ECG for baseline comparison - Echocardiogram (structural context) - Sleep study results if sleep-related arrhythmia suspected --- ## Step 1: Device Selection Appropriateness Assessment **Device-to-Indication Matching (HRS Consensus):** | Symptom Frequency | Recommended Device | Duration | |------------------|-------------------|----------| | Daily | 24–48 hour Holter | 1–2 days | | Several times/week | Extended Holter or patch monitor | 7–14 days | | Weekly to monthly | Event recorder or MCT | 30 days | | Infrequent (< monthly) | Implantable loop recorder (ILR) | Up to 3 years | | Cryptogenic stroke (AF detection) | ILR preferred; MCT × 30 days as alternative | ILR: 6–36 months | | Post-ablation AF recurrence | 7-day Holter or patch at set intervals | Per protocol | **Document:** Was the selected device appropriate for the clinical question? If monitoring duration was insufficient to capture symptoms, recommend extended monitoring. --- ## Step 2: Baseline Rhythm and Rate Analysis **Heart Rate Summary:** - Minimum HR with time and rhythm at minimum - Maximum HR with time, activity, and rhythm at maximum - Average HR over the recording period - Heart rate variability (SDNN if reported — reduced SDNN < 50 ms associated with increased cardiac mortality) **Baseline Rhythm Assessment:** - Predominant rhythm: normal sinus, sinus bradycardia, sinus tachycardia, atrial fibrillation, atrial flutter, paced - Sinus node function: appropriate rate variability, chronotropic response to activity - AV conduction: PR interval consistency, presence of AV block episodes (first-degree, Mobitz I, Mobitz II, complete) - Pauses: longest R-R interval, duration, mechanism (sinus pause, sinus arrest, AV block) **Pause Significance:** | Duration | Clinical Significance | |----------|----------------------| | < 2.0 s | Normal (may occur during sleep) | | 2.0–2.9 s | Borderline; correlate with symptoms | | ≥ 3.0 s (awake) | Significant; evaluate for sinus node dysfunction or AV block | | ≥ 3.0 s (sleep) | May be physiologic in young, athletic patients; correlate | --- ## Step 3: Arrhythmia Event Analysis and Quantification **Supraventricular Events:** - Isolated PACs: count total, calculate burden (% of total beats) - PAC burden > 10,000/day or > 10% associated with increased AF risk and cardiomyopathy - SVT episodes: number, duration, peak rate, mechanism if identifiable (AVNRT, AVRT, AT) - Atrial fibrillation: total burden (hours or % of recording time), longest episode, average ventricular rate during AF - Atrial flutter: episodes, rate, duration **AF Burden Quantification:** | Burden | Clinical Significance | |--------|----------------------| | < 0.5% | Minimal; reassess anticoagulation need based on CHA2DS2-VASc | | 0.5–5% | Low-moderate; anticoagulation per CHA2DS2-VASc | | 5–50% | Moderate-high; consider rhythm control | | > 50% | High burden; persistent AF pattern | **Ventricular Events:** - Isolated PVCs: total count, burden (% of total beats) - PVC burden > 10–15% associated with PVC-induced cardiomyopathy - PVC morphology: uniform (single focus) vs. multiform - Couplets: frequency - NSVT episodes: number, duration (beats), rate - Sustained VT (≥ 30 seconds or hemodynamically unstable): URGENT — report immediately - R-on-T phenomenon: flag as high risk for VF **PVC Burden Significance:** | Burden | Recommendation | |--------|---------------| | < 5% | Typically benign; reassure | | 5–10% | Monitor; echo if symptoms or concern for cardiomyopathy | | 10–15% | Echo for cardiomyopathy screening; consider suppressive therapy | | > 15% | High risk for cardiomyopathy; ablation evaluation | --- ## Step 4: Symptom-Rhythm Correlation **Correlation Categories:** 1. **Positive correlation:** Symptom occurred simultaneously with arrhythmia → arrhythmia is the cause 2. **Negative correlation:** Symptom occurred during normal sinus rhythm → arrhythmia is NOT the cause (equally important diagnostically) 3. **Non-diagnostic:** Symptoms occurred but no interpretable rhythm at that time, or no symptoms occurred during monitoring **Document for each diary entry:** - Timestamp of symptom - Rhythm at that exact time - Heart rate at that time - Correlation conclusion **If no symptoms occurred during monitoring:** State explicitly — "No patient-activated events during the monitoring period; study non-diagnostic for symptom-rhythm correlation. Consider extended monitoring." --- ## Step 5: Structured Report and Recommendations **Report Template:** 1. Indication for monitoring 2. Device type and total recording duration (analyzable %) 3. Predominant rhythm 4. Heart rate summary: minimum, maximum, average 5. Supraventricular events: PAC count/burden, SVT episodes (type, rate, duration), AF burden 6. Ventricular events: PVC count/burden, morphology, couplets, NSVT, sustained VT 7. Conduction abnormalities: AV block episodes, pauses (longest, mechanism) 8. ST-segment changes (if monitored) 9. Symptom-rhythm correlation 10. Comparison with prior study 11. Conclusions and recommendations --- ## Checkpoint B: Post-Draft Alignment (Mandatory) 1. Is the arrhythmia burden quantified (not just "present" or "absent")? 2. Is symptom-rhythm correlation addressed for every diary entry? 3. Are PVC and PAC burdens calculated as percentage of total beats? 4. Are high-risk findings (sustained VT, long pauses, high AF burden) flagged? 5. Is device appropriateness assessed for the clinical question? --- ## Quality Audit - [ ] Device type and recording duration documented - [ ] Analyzable time percentage reported - [ ] Predominant rhythm identified - [ ] Heart rate summary with minimum, maximum, and average - [ ] Supraventricular event quantification (PAC count and burden %) - [ ] AF burden calculated as hours and/or percentage of recording - [ ] Ventricular event quantification (PVC count and burden %) - [ ] PVC morphology described (uniform vs. multiform) - [ ] NSVT episodes documented with rate and duration - [ ] Pauses documented with duration and mechanism - [ ] Symptom-rhythm correlation addressed for every diary entry - [ ] High-risk findings flagged with urgency level - [ ] Comparison with prior monitoring study if available - [ ] Recommendations include next steps (extended monitoring, echo, ablation, device) --- ## Guidelines 1. Always quantify arrhythmia burden as a percentage of total beats — qualitative terms like "frequent" or "occasional" are clinically insufficient. 2. PVC burden > 10% warrants echocardiographic screening for PVC-induced cardiomyopathy, and burden > 15% should prompt ablation evaluation. 3. AF burden assessment requires documenting total AF duration as a proportion of recording time — single-episode duration alone does not capture intermittent burden. 4. Symptom-rhythm NEGATIVE correlation (symptoms during sinus rhythm) is diagnostically valuable and should be clearly reported. 5. Pauses ≥ 3 seconds during wakefulness require clinical evaluation for sinus node dysfunction or AV block regardless of symptoms. 6. When monitoring fails to capture symptoms (non-diagnostic study), recommend the appropriate next-step device based on symptom frequency. 7. In cryptogenic stroke patients, AF detection requires at least 30 seconds of continuous AF per current guidelines to warrant anticoagulation — shorter episodes remain an area of active study. 8. Heart rate variability metrics should be reported when available, as reduced SDNN is an independent predictor of cardiac mortality in post-MI and HF patients.